INS and type 1 diabetes mellitus: Recent clinical trial data (Ovalle et al. 2018, Xu et al. 2022) demonstrate that continuous oral use of the approved blood pressure medication, verapamil, in subjects with T1D delays loss of beta cell function and lowers insulin requirements for at least 2 years post-diagnosis.